Feline hyperthyroidism is the most common endocrine disease in older cats. Effective treatments exist, but diagnosis gaps and treatment access remain welfare challenges.
Feline hyperthyroidism represents a genuine welfare success story: a disease that was once unrecognized and universally fatal is now routinely managed with good outcomes through a range of treatment options. However, the welfare success is incomplete. Diagnosis gaps exist because cats hide illness and owners may attribute weight loss or behavioral changes to normal aging. Treatment gaps exist because radioactive iodine — the most effective treatment — is expensive and requires specialist referral not accessible to all owners. Medication compliance requires daily pilling that stresses many cats. Dietary management requires strict exclusion from all other food sources. The welfare ideal is early screening for all senior cats, accessible treatment options at different price points, and management that considers the cat's quality of life during treatment.